CNBC Investing Club

Cramer's Investing Club Stock Profile: Drugmaker Abbvie deserves a lot more love from the market

A sign stands outside a Abbvie facility in Cambridge, Massachusetts, May 20, 2021.
Brian Snyder | Reuters

Abbvie (ABBV) is a leading biopharmaceutical firm that's transformed itself from a mostly one-drug company to a diversified business after the 2020 acquisition of Allergan.

More In CNBC Investing Club

CNBC Investing ClubSnap's ad warning hits Facebook and Google shares. We say don't join the sellers
CNBC Investing ClubWe're high-grading in tech and finance, paying for it with a casino sale
watch now
CNBC Investing ClubTuesday, May 24, 2022: Impact of earnings reports and guidance on stocks